Omeros Earnings Call Transcripts
Fiscal Year 2026
-
YARTEMLEA achieved $32.2M in gross sales and $13.2M net income in its first full quarter, with strong adoption and positive cash flow. Capital structure was strengthened through share and note repurchases, and CMS granted favorable reimbursement. The company expects continued growth and aims for cash flow positivity by mid-2027.
-
The meeting approved all proposals, including director elections and compensation plans, and highlighted a transformative year with the YARTEMLEA launch, strengthened financials, and pipeline progress. Management addressed shareholder questions on product adoption, competition, and capital strategy.
-
YARTEMLEA's U.S. launch drove $9.9M in Q1 net revenue with rapid adoption and strong payer support. Novo Nordisk deal secured $240M upfront, and the company ended Q1 with $135.3M in cash. CMS J-code and NTAP are expected to further boost access and reimbursement.
-
YARTEMLEA received FDA approval as the first therapy for TA-TMA, showing strong efficacy and a favorable safety profile. The launch is expected to shift treatment paradigms, with broad label coverage, robust reimbursement support, and a focus on early intervention and outpatient use.
Fiscal Year 2025
-
Q4 2025 saw a transformative asset sale to Novo Nordisk and FDA approval plus rapid U.S. launch of YARTEMLEA, driving a swing to profitability and strengthening the balance sheet. Early YARTEMLEA adoption is robust, with strong payer and formulary support.
-
Q3 2025 saw a net loss of $30.9M, with adjusted net loss at $22.1M. A major Novo Nordisk deal for Zaltenibart is set to bring $240M upfront, supporting debt repayment and the Yartemlya launch, which awaits FDA approval by year-end.
-
Q2 2025 net loss narrowed to $25.4M, with cash bolstered by a $20.6M offering and major debt reduction. Narsoplimab's FDA review is ongoing, with a PDUFA date set for December, and advanced partnership talks could provide significant upfront capital.
-
Q1 2025 saw a net loss of $33.5 million and significant debt restructuring, reducing near-term obligations by over $100 million. Focus remains on the anticipated Narsoplimab launch for TATMA, with FDA action expected by September 2025, while other programs are paused or limited.
Fiscal Year 2024
-
Q4 2024 net loss narrowed to $31.4M, with over $90M in cash. Narsoplimab BLA resubmitted for TA-TMA, with strong survival data and a PDUFA date in September. Zaltenibart phase III PNH trials progressing, and multiple financing options are being pursued.
-
Q3 2024 net loss narrowed to $32.2 million, driven by lower R&D expenses. OMIDRIA sales are set to grow with expanded reimbursement, and narsoplimab BLA resubmission is imminent, targeting commercial launch in 2025. Zaltenibart Phase III trials are underway for PNH and C3G.
-
Q2 2024 saw a net loss of $56 million, driven by one-time manufacturing and debt repurchase costs, but the balance sheet was strengthened by reducing and extending debt maturities. Key development programs, including narsoplimab and zaltenibart, are advancing, with pivotal trials and regulatory milestones expected in late 2024 and early 2025.